2. Disease Areas
  3. Digestive System Disease
  4. Digestive System Cancer
  5. Esophageal Cancer

Esophageal Cancer

Esophageal cancer is a malignant tumor that originates in the lining of the esophagus, the tube connecting the mouth to the stomach, characterized by uncontrolled cell growth. The two primary types are squamous cell carcinoma, often linked to smoking, heavy alcohol use, and GERD, and adenocarcinoma, associated with obesity, Barrett’s esophagus, and family history. Common symptoms include difficulty swallowing, weight loss, chest pain, hoarseness, and coughing up blood, especially in advanced stages. Risk factors include lifestyle choices such as tobacco and alcohol use, poor diet, and chronic inflammation from conditions like GERD or H. pylori infection. Diagnosis can be challenging due to nonspecific early symptoms. Treatment typically involves surgery, chemotherapy, radiation therapy, or a combination, depending on stage and patient health. Esophageal cancer is more prevalent in men and individuals over 60, and remains a leading cause of cancer-related deaths worldwide.

Esophageal Cancer (15):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-18768
    NCT-501 1802088-50-1 99.59%
    NCT-501 is a reversible, non-competitive, selective, blood-brain barrier-permeable ALDH1A1 inhibitor with an IC50 of 40 nM. NCT-501 inhibits the AKT-β-catenin signaling pathway, induces necroptosis in nasopharyngeal carcinoma cells, suppresses their proliferation and inhibits stem cell spheroid formation. NCT-501 can be used in research related to nasopharyngeal carcinoma, esophageal squamous cell carcinoma and malignant tumors.
    NCT-501
  • HY-N3415
    Kumatakenin 3301-49-3 99.31%
    Kumatakenin is an orally active apoptosis inducer and autophagy inhibitor, with a Kd value of 2.94 μM for mouse ATG5. Kumatakenin increases the activities of caspase-3, caspase-8 and caspase-9, thereby inducing caspase-dependent apoptosis in ovarian cancer cells. Kumatakenin reduces the expression of chemokines and pro-oncogenic factors in ovarian cancer cells, and inhibits M2 macrophage polarization. Kumatakenin inactivates TRIM65 function, reduces the expression and stability of FASN, and thus inhibits the proliferation, migration, invasion and tumor progression of esophageal cancer cells. Kumatakenin interacts with ATG5 to reduce its protein level, decrease LC3 level, and reduce the number of autophagosomes in the hippocampus. Kumatakenin binds to Eno3 to upregulate its expression, reduce the stability and expression level of IRP1 mRNA, inhibit ferroptosis, alleviate intestinal inflammation, and restore epithelial barrier function. Kumatakenin enhances the efficacy of antibiotics against pathogenic bacteria, inhibits SARS-CoV-2 replication, and reduces cytokine production. Kumatakenin is applicable to research related to ovarian cancer, esophageal cancer, depression and colitis.
    Kumatakenin
  • HY-156418
    KY386 2787598-01-8 99.01%
    KY386 is a DHX33 helicase inhibitor with an IC50 of 0.019 μM. KY386 inhibits the cell viability of various cancer cells. KY386 induces ferroptosis in cancer cells, and induces apoptosis in some cancer cell lines. KY386 increases the intracellular levels of ROS, LPO and Fe2+, and decreases the level of GSH in cancer cells. KY386 inhibits the growth of gastric cancer and colon cancer xenografts in nude mice. KY386 is applicable to the related research on liver cancer, lung cancer, pancreatic cancer, colorectal cancer, gastric cancer, breast cancer, leukemia, renal cancer, prostate cancer, esophageal cancer, cervical cancer, brain cancer (glioblastoma) and melanoma.
    KY386
  • HY-N6723
    Fumonisin B2 116355-84-1 99.99%
    Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma.
    Fumonisin B2
  • HY-169766
    VVD 065 3034876-85-9 99.71%
    VVD 065 is an orally active KEAP1-dependent NRF2 molecular glue degrader with a KEAP1 KD of 65 nM. VVD 065 covalently engages KEAP1 at Cys151, allosterically stabilizes KEAP1-CUL3 complex formation and enhances NRF2 polyubiquitination and proteasomal degradation. VVD 065 can be used for the research of esophageal squamous cell carcinoma, lung cancer, head-and-neck cancer, uterine cancers.
    VVD 065
  • HY-186206
    (Rac)-EGC-M7 509078-28-8
    (Rac)-EGC-M7 is a racemic microbial metabolite of green tea Catechin (EGC) (HY-N0898), and acts as an inhibitor of nitric oxide production and cancer cell growth. (Rac)-EGC-M7 can be used in the research of esophageal squamous cell carcinoma and colon adenocarcinoma.
    (Rac)-EGC-M7
  • HY-180897
    RSK4-IN-2 3034203-03-4
    RSK4-IN-2 (compound 16o) is a potent, orally active RSK4 inhibitor with an IC50 of 17 nM. RSK4-IN-2 suppresses esophageal squamous cell carcinoma (ESCC) cell growth and invasion, by inhibiting phosphorylation of RSK4 downstream targets. RSK4-IN-2 inhibits tumor growth and metastasis in ESCC mouse models. RSK4-IN-2 can be used for ESCC research.
    RSK4-IN-2
  • HY-120548
    KBU2046 1143863-69-7 99.52%
    KBU2046 is an orally active transforming growth factor-β (TGF-β1) inhibitor. KBU2046 reduces integrin family protein expression, decreases Raf, RIPK1 and ERK phosphorylation to deactivate the ERK signaling pathway, and down-regulates genes linked to TGF-β1 maturation. KBU2046 suppresses tumor cell motility, impedes cancer invasion and metastasis, and inhibits human ESCC growth and metastasis in a murine model. KBU2046 can be used for the researches of triple-negative breast cancer and esophageal squamous cell carcinoma.
    KBU2046
  • HY-P991342
    CQY684
    CQY684 (PCA062 antibody) is a monoclonal antibody targeting CDH3/P-cadherin, which locks P-cadherin in an X-dimer conformation and enhances the stability of this adhesion structure. CQY684 induces P-cadherin phosphorylation and promotes its dissociation from the cytoplasmic region of P-cadherin. As an endocytosis inducer and lysosome-targeting agent, CQY684 facilitates the internalization of the P-cadherin-CQY684 complex and improves the turnover efficiency of P-cadherin. CQY684 serves as a platform for the delivery of intracellular anticancer compounds, which is achieved through the targeted lysosomal transport of the antibody-P-cadherin complex. CQY684 is applicable to the research of breast cancer, esophageal cancer, and head and neck cancer.
    CQY684
  • HY-173135
    PROTAC KDM4 degrader-1 3102423-10-6
    PROTAC KDM4 degrader-1 is a KDM4 PROTAC degrader that degrades KDM4A-C with DC50 values of 37.53, 39.93, and 49.41 nM, respectively, while sparing KDM4D. PROTAC KDM4 degrader-1 induces cell cycle arrest, apoptosis and antiproliferative activity in esophageal cancer cells. PROTAC KDM4 degrader-1 can be used for the research of esophageal cancer.
    PROTAC KDM4 degrader-1
  • HY-183147A
    LAT1-IN-2 hydrochloride
    LAT1-IN-2 hydrochloride is an orally active anticancer agent, as well as a LAT1 substrate and tubulin-binding agent. LAT1-IN-2 hydrochloride relies on LAT1 for cellular uptake, disrupts microtubule formation by binding to the colchicine site of tubulin, and induces actin depolymerization to transform cells into a spherical shape. LAT1-IN-2 hydrochloride effectively inhibits tumor growth in xenograft mice. Compared with Etoposide (HY-13629), LAT1-IN-2 hydrochloride shows higher distribution in tumor tissues, lower distribution in major organs, and better tolerability. LAT1-IN-2 hydrochloride has been applied in studies related to esophageal cancer.
    LAT1-IN-2 hydrochloride
  • HY-N18236
    3β-Acetoxyl-atractylenolide I 2538955-98-3
    3β-Acetoxyl-atractylenolide I is a LSD1 inhibitor with an IC50 of 57 μM. 3β-Acetoxyl-atractylenolide I blocks tumor growth, metastasis and invasion. 3β-Acetoxyl-atractylenolide I is used in the research of various cancers including prostate cancer, breast cancer, neuroblastoma, gastric cancer, colon cancer, bladder cancer, esophageal cancer, acute myeloid leukemia and retinoblastoma.
    3β-Acetoxyl-atractylenolide I
  • HY-N17751
    Phaseoloideside D 1259326-81-2
    Phaseoloideside D is an oleanane-type triterpene saponin. Phaseoloideside D can be found in the seeds of *Entada phaseoloides*. Phaseoloideside D exhibits cytotoxicity against esophageal cancer, liver cancer, and cervical cancer cells. Phaseoloideside D can be used in colon cancer research.
    Phaseoloideside D
  • HY-N17752
    Phaseoloideside C 1453187-72-8
    Phaseoloideside C is an oleanane-type triterpenoid saponin. Phaseoloideside C can be isolated from the seeds of *Entada phaseoloides*. Phaseoloideside C exhibits no cytotoxicity against hepatocellular carcinoma cells, esophageal carcinoma cells, cervical carcinoma cells, and colon carcinoma cells .
    Phaseoloideside C
  • HY-N19220
    Radiclonic acid 49620-14-6
    Radiclonic acid acts as an antibacterial agent, anticancer agent, and root growth promoter. Radiclonic acid is isolable from fungi of the genus Penicillium. Radiclonic acid exhibits antibacterial activity against MRSA with a MIC of 3.13 μg/mL. Radiclonic acid shows anticancer activity against esophageal cancer, bladder cancer, and liver cancer. Radiclonic acid promotes root growth in Chinese cabbage seedlings. Radiclonic acid is inactive against pancreatic cancer and cervical cancer. Radiclonic acid can be used in research related to Staphylococcus aureus infection, bladder cancer, esophageal cancer, and liver cancer.
    Radiclonic acid